Clinical Trial Update: Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade

View source ↗

Summary

A clinical trial is evaluating a combination of an IDO1 inhibitor and PD-1 blockade to target the immunosuppressive microenvironment in acute myeloid leukemia; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna | Conditions: AML (Acute Myelogenous Leukemia) | Status: RECRUITING